{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:08:34Z","timestamp":1793992114361,"version":"4.8.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105826","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:04:30Z","timestamp":1759997070000},"page":"105826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-0065","authenticated-orcid":false,"given":"D.","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-284X","authenticated-orcid":false,"given":"T.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-6125","authenticated-orcid":false,"given":"J.J.X.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-Y.","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0029","authenticated-orcid":false,"given":"M.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-C.","family":"Jeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tan Chun Bing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-0175","authenticated-orcid":false,"given":"K.","family":"Korphaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tanasanvimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.-C.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cargullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-8032","authenticated-orcid":false,"given":"N.F.A.","family":"Muin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-0574","authenticated-orcid":false,"given":"M.A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bondarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.R.A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-1817","authenticated-orcid":false,"given":"E.C.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-3255","authenticated-orcid":false,"given":"G.","family":"Bonney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2462","authenticated-orcid":false,"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-3528","authenticated-orcid":false,"given":"J.","family":"Samol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3691","authenticated-orcid":false,"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-3408","authenticated-orcid":false,"given":"E.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MPA.0000000000001222","article-title":"The distributional characteristic and growing trend of pancreatic cancer in China","volume":"48","author":"Zhao","year":"2019","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4143\/crt.2023.447","article-title":"Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020","volume":"55","author":"Kang","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.105826_bib9","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2020"},{"key":"10.1016\/j.esmoop.2025.105826_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1271370","article-title":"Pancreatic cancer challenge in 52 Asian countries: age-centric insights and the role of modifiable risk factors (1990-2019)","volume":"13","author":"Xiang","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105826_bib11","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/cancers15082216","article-title":"Rare non-neuroendocrine pancreatic tumours","volume":"15","author":"Mormul","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"43","key":"10.1016\/j.esmoop.2025.105826_bib12","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmoop.2025.105826_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102196","article-title":"World-wide trends in net survival from pancreatic cancer by morphological sub-type: an analysis of 1,258,329 adults diagnosed in 58 countries during 2000-2014 (CONCORD-3)","volume":"80","author":"Niksic","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105826_bib14","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1158\/1055-9965.EPI-18-1327","article-title":"Smoking and pancreatic cancer incidence: a pooled analysis of 10 population-based cohort studies in Japan","volume":"28","author":"Koyanagi","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105826_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105826_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jhbp.1117","article-title":"The incidence and clinical features of familial pancreatic cancer in Korea","volume":"29","author":"Kim","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105826_bib17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3748\/wjg.v23.i6.935","article-title":"Familial pancreatic cancer: concept, management and issues","volume":"23","author":"Matsubayashi","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-024-01008-7","article-title":"Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan","volume":"31","author":"Cheng","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.esmoop.2025.105826_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103033","article-title":"Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes","volume":"60","author":"Mizukami","year":"2020","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48721","article-title":"Prevalence of germline sequence variations among patients with pancreatic cancer in China","volume":"5","author":"Yin","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"issue":"92","key":"10.1016\/j.esmoop.2025.105826_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002543","article-title":"Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development","volume":"3","author":"Wu","year":"2011","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105826_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104528","article-title":"ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer","volume":"10","author":"Conroy","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105826_bib25","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105826_bib26","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105826_bib29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105826_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib31","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/jcm13072103","article-title":"The clinical implications of KRAS mutations and variant allele frequencies in pancreatic ductal adenocarcinoma","volume":"13","author":"Nusrat","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.surg.2014.06.016","article-title":"Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)","volume":"156","author":"Tol","year":"2014","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105826_bib33","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1097\/SLA.0000000000003558","article-title":"Significance of examined lymph node number in accurate staging and long-term survival in resected stage I-II pancreatic cancer-more is better? A large international population-based cohort study","volume":"274","author":"Huang","year":"2021","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.21037\/jgo-20-158","article-title":"Impact of examined lymph node count on prognosis in patients with lymph node-negative pancreatic body\/tail ductal adenocarcinoma","volume":"11","author":"Li","year":"2020","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1245\/s10434-021-10797-2","article-title":"A novel criterion for lymph nodes dissection in distal pancreatectomy for ductal adenocarcinoma: a population study of the US SEER database","volume":"29","author":"Wang","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105826_bib36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ags3.12796","article-title":"Randomized, controlled, multi-center phase II study of postoperative enoxaparin treatment for venous thromboembolism prophylaxis in patients undergoing surgery for hepatobiliary-pancreatic malignancies","volume":"8","author":"Shinke","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib37","article-title":"Anticoagulation for perioperative thromboprophylaxis in people with cancer","volume":"7","author":"Matar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0903230","article-title":"Preoperative biliary drainage for cancer of the head of the pancreas","volume":"362","author":"van der Gaag","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib39","article-title":"Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgery","volume":"2007","author":"Mumtaz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105826_bib40","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1245\/s10434-024-15011-7","article-title":"Adjuvant gemcitabine versus neoadjuvant\/adjuvant FOLFIRINOX in resectable pancreatic cancer: the randomized multicenter phase II NEPAFOX trial","volume":"31","author":"Goetze","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105826_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","article-title":"Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05)","volume":"37","author":"Unno","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","article-title":"Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis","volume":"28","author":"Okusaka","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105826_bib44","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"10041","key":"10.1016\/j.esmoop.2025.105826_bib45","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105826_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2021.08.002","article-title":"Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: a randomised controlled trial (MPACA-3)","volume":"157","author":"Go","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105826_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102817","article-title":"Adjuvant treatment for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis","volume":"145","author":"Parmar","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10073","key":"10.1016\/j.esmoop.2025.105826_bib48","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"46","key":"10.1016\/j.esmoop.2025.105826_bib49","doi-asserted-by":"crossref","first-page":"81419","DOI":"10.18632\/oncotarget.19082","article-title":"Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105826_bib50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaoncol.2021.5407","article-title":"Patterns of adjuvant chemotherapy use and association with survival in adults 80 years and older with pancreatic adenocarcinoma","volume":"8","author":"Mehtsun","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.esmoop.2025.105826_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2304","article-title":"LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS\/PRODIGE 44","volume":"35","author":"Lambert","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105826_bib54","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib55","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1245\/s10434-023-13353-2","article-title":"FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review","volume":"30","author":"Eshmuminov","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.105826_bib56","article-title":"Randomized phase II\/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study","volume":"42","author":"Ikeda","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105826_bib57","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2025.105826_bib58","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105826_bib59","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105826_bib60","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105826_bib62","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cancers11040484","article-title":"Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"11","author":"Pusceddu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.105826_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2565","article-title":"1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II\/III trial","volume":"34","author":"Ohba","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.105826_bib66","article-title":"Early results of the PASS-01 trial: pancreatic adenocarcinoma signature stratification for treatment-01","volume":"42","author":"Knox","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib67","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci Rep"},{"issue":"10409","key":"10.1016\/j.esmoop.2025.105826_bib68","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105826_bib69","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2024.42.16_suppl.4003","article-title":"A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na\u00efve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186","volume":"42","author":"Dotan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105826_bib70","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105826_bib71","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and paclitaxel versus gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: a randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study","volume":"42","author":"De La Fouchardiere","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105826_bib72","article-title":"How I treat pancreatic cancer","volume":"4","author":"Taieb","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.105826_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211056179","article-title":"Gemcitabine plus nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial","volume":"13","author":"Huh","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2025.105826_bib74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105826_bib75","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s12885-016-2798-8","article-title":"Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)","volume":"16","author":"Vogel","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2025.105826_bib80","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0959-8049(22)01000-0","article-title":"Update from the ongoing phase 1\/2 registrational trial of repotrectinib: results in TKI-na\u00efve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)","volume":"174","author":"Besse","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105826_bib81","article-title":"Response to repotrectinib after development of NTRK resistance mutations on first- and second-generation TRK inhibitors","volume":"7","author":"Chen","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2025.105826_bib82","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamasurg.2024.5024","article-title":"Routine imaging or symptomatic follow-up after resection of pancreatic adenocarcinoma","volume":"160","author":"Andel","year":"2025","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib84","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib85","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/cancers12030618","article-title":"Primary thromboprophylaxis in pancreatic cancer patients: why clinical practice guidelines should be implemented","volume":"12","author":"Farge","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105826_bib86","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2019-128674","article-title":"Updated meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis (PATP) in patients with advanced pancreatic cancer (APC) receiving chemotherapy","volume":"134","author":"Thein","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105826_bib87","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105826_bib88","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1002\/cam4.3269","article-title":"Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study","volume":"9","author":"Vadhan-Raj","year":"2020","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105826_bib89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/cancers10120501","article-title":"Venous thromboembolism in Asian patients with pancreatic cancer following palliative chemotherapy: low incidence but a negative prognosticator for those with early onset","volume":"10","author":"Chen","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.105826_bib90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thromres.2021.09.012","article-title":"One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: results from the cancer-VTE registry","volume":"213","author":"Ohashi","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.esmoop.2025.105826_bib91","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12885-015-1200-6","article-title":"Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study","volume":"15","author":"Chew","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105826_bib92","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1055\/a-0659-9864","article-title":"Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017","volume":"50","author":"Dumonceau","year":"2018","journal-title":"Endoscopy"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105826_bib93","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4103\/0366-6999.180530","article-title":"Palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer: a meta-analysis comparison of gastrojejunostomy with endoscopic stenting","volume":"129","author":"Bian","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib94","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-006-2003-y","article-title":"Endoscopic stenting versus surgical gastroenterostomy for palliation of malignant gastroduodenal obstruction: a meta-analysis","volume":"42","author":"Hosono","year":"2007","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.esmoop.2025.105826_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-230X-7-18","article-title":"Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review","volume":"7","author":"Jeurnink","year":"2007","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1443-1661.2011.01186.x","article-title":"Endoscopic stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction","volume":"24","author":"Zheng","year":"2012","journal-title":"Dig Endosc"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105826_bib97","doi-asserted-by":"crossref","first-page":"E1158","DOI":"10.1055\/s-0042-115935","article-title":"Stents and surgical interventions in the palliation of gastric outlet obstruction: a systematic review","volume":"4","author":"Minata","year":"2016","journal-title":"Endosc Int Open"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib98","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S2468-1253(23)00242-X","article-title":"Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial","volume":"9","author":"Teoh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Chiorean","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/cancers16030489","article-title":"Anatomical and biological considerations to determine resectability in pancreatic cancer","volume":"16","author":"Rompen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib102","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/jhbp.1049","article-title":"New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS)","volume":"29","author":"Oba","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4240\/wjgs.v15.i2.142","article-title":"Comprehensive multimodal management of borderline resectable pancreatic cancer: current status and progress","volume":"15","author":"Wu","year":"2023","journal-title":"World J Gastrointest Surg"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105826_bib104","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdg119","article-title":"An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin\/5-fluorouracil every 2 weeks in patients with advanced solid tumors","volume":"14","author":"Ychou","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105826_bib106","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4251\/wjgo.v10.i11.421","article-title":"Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer","volume":"10","author":"Kang","year":"2018","journal-title":"World J Gastrointest Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105826_bib107","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.3390\/cancers16193395","article-title":"Tissue-agnostic targeting of neurotrophic tyrosine receptor kinase fusions: current approvals and future directions","volume":"16","author":"Gouda","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib108","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105826_bib109","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105826_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1013902","article-title":"KRAS G12D targeted therapies for pancreatic cancer: has the fortress been conquered?","volume":"12","author":"Bannoura","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105826_bib112","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.3390\/molecules28083615","article-title":"Multiple strategies to develop small molecular KRAS directly bound inhibitors","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105826_bib113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105826_bib114","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib115","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph16040614","article-title":"Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.esmoop.2025.105826_bib116","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241253113","article-title":"Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series","volume":"16","author":"Mehdi","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib117","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s43441-022-00486-x","article-title":"Changes in the review period of drug application and a drug lag from the FDA and the EMA: an Industry survey in South Korea between 2011 and 2020","volume":"57","author":"Choi","year":"2023","journal-title":"Ther Innov Regul Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105826_bib118","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jso.23921","article-title":"Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability","volume":"111","author":"Nanda","year":"2015","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib119","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","article-title":"Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas","volume":"22","author":"Blazer","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105826_bib120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41416-020-0867-x","article-title":"Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a phase 2 study for clinical and biomarker analysis","volume":"123","author":"Yoo","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105826_bib121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/apc-23-6","article-title":"Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic adenocarcinoma\u2014a single-center experience in India","volume":"6","author":"Soni","year":"2023","journal-title":"Ann Pancreat Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105826_bib122","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","author":"Stein","year":"2016","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib123","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.30125","article-title":"First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: patients\u2019 outcome and analysis of prognostic factors","volume":"139","author":"Vivaldi","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2025.105826_bib124","doi-asserted-by":"crossref","first-page":"413","DOI":"10.14735\/amgh2016413","article-title":"Modified FOLFIRINOX in the treatment of pancreatic cancer \u2013 efficiency and toxicity","volume":"70","author":"Vocka","year":"2016","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105826_bib125","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/cam4.4512","article-title":"Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI\/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: a real-world analysis","volume":"11","author":"Tezuka","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2025.105826_bib126","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2017.07.012","article-title":"Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population","volume":"406","author":"Li","year":"2017","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105826_bib127","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","article-title":"Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma","volume":"42","author":"Mahaseth","year":"2013","journal-title":"Pancreas"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925016953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925016953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:59:31Z","timestamp":1772895571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925016953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925016953"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105826","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105826"}}